Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway

Autor: Audun Ohna, Fredrik Salvesen Haukaas, Tania Krivasi

Publikováno v: Applied health economics and health policy. 16(4)

To evaluate the cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinituzumab maintenance (Obin-Benda) compared to bendamustine alone (Benda) in patients with refractory follicular lymphoma (FL) in a Norwegian setting.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b8c73efdce459ce90c676b1b782f75
https://pubmed.ncbi.nlm.nih.gov/29923173

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain

Autor: Eva González-Haba, Carlos Rubio-Terrés, Javier Loscertales, Tania Krivasi, Luis Felipe Casado, Amparo Burgos, Darío Rubio-Rodríguez, Javier Orofino

Publikováno v: ClinicoEconomics and Outcomes Research
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
ClinicoEconomics and Outcomes Research, Vol Volume 8, Pp 475-484 (2016)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
ClinicoEconomics and Outcomes Research: CEOR
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Luis Felipe Casado,1 Amparo Burgos,2 Eva González-Haba,3 Javier Loscertales,4 Tania Krivasi,5 Javier Orofino,6 Carlos Rubio-Terres,7 Darío Rubio-Rodríguez7 1Hematology Department, Hospital Virgen de la Salud, Toledo, Spain; 2Pharmacy Department, H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1982407f8b374357517a4e2fe2a21d3
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1662

Mapping from SF-36 Trial Data To EQ-5D Utilities in Advanced Basal Cell Carcinoma

Autor: AJ Hatswell, A Reyes, Tania Krivasi, T Loughran, Mark Pletscher

Publikováno v: Value in Health. 20:A449

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::501eeec5f8cd422aa9eeae9fc94a3053
https://doi.org/10.1016/j.jval.2017.08.287

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Autor: Kenneth Wilhelm, Anthony Masaquel, David L. Veenstra, Tania Krivasi, Carolina Reyes, Gregory F. Guzauskas

Publikováno v: Blood. 128:3605-3605

Background. Obinutuzumab (G) was recently approved for the treatment of follicular lymphoma (FL) in patients who relapsed after or are refractory to a rituximab (R)-containing regimen. In the phase III open label GADOLIN study of patients with rituxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6af6273554ae0eefd23c1b6ccef4266d
https://doi.org/10.1182/blood.v128.22.3605.3605